Meds & supplements › Imetelstat
Medicine
The following clinically significant adverse reactions are described elsewhere in the labeling:
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
None.
Storage
Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in original carton.
Do not freeze.
sofidex [Internet]. Daloreum; c2026. Imetelstat; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/imetelstat
sofidex. (2026, August 3). Imetelstat. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/imetelstat
Imetelstat. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/imetelstat
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.